A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DIMEBON [PF 01913539] IN SUBJECTS WITH SEVERELY-IMPAIRED AND NORMAL RENAL FUNCTION: